BioSpecifics Technologies has named George Gould to its board of directors effective December 6, 2011. Gould, an attorney, is principal of George M. Gould and of counsel to Gibbons PC.

"We are delighted that George has joined our board of directors. He has sat on the board of a number of public pharmaceutical companies and was at Hoffmann-La Roche for 28 years as a vice president in licensing and IP. I believe his experience and expertise will be invaluable to BioSpecifics as XIAFLEX advances toward approval in several new clinical indications," said Thomas Wegman, president of BioSpecifics.